2022³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãß°èÇмú´ëȸ : 2022-12-10±³À°ÀÏÀÚ : 2022-12-10
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ / ÄÁÆÛ·±½º·ë 1~3
±³À°ÁÖÁ¦ :
2022³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ(ÀÎ)
´ã´çÀÚ : ÃÖÀº¿µ
¿¬¶ôó : 070-8873-6030
À̸ÞÀÏ :
k-iscp@naver.com ±³À°Á¾·ù : ³»°ú, ½Å°æ¿Ü°úÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 08:50~09:00 Opening ¿Â¿µ±Ù(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 09:00~09:20 Hypertensive medications in CKD ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 09:20~09:40 Diabetic medications in CKD ¹®ÁÖ¿µ(°æÈñÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 09:40~10:00 Anticoagulation in CKD ±èÀ±±â(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 10:00~10:20 Several issues in treating CKD patients with cardiac diseases ±èÁ°æ(ÇѸ²ÀÇ´ë ½ÅÀå³»°ú)
Åä·Ð 12-10 ´ë¾çAIȦ 10:20~10:30 Åä·Ð ()
ÈÞ½Ä 12-10 ´ë¾çAIȦ 10:30~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 10:50~11:10 Nootropics ÀÓÀ缺(¿ï»êÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 11:10~11:30 RAS inhibitor: antiarrhythmia and glucose lowering effect Á¤Çý¹®(°æÈñÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 11:30~11:50 Omega-3 fatty acid: antiarrhythmic effect ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 11:50~12:10 Statin: Diabetogenic effect ±¸º¸°æ(¼¿ïÀÇ´ë ³»ºÐºñ´ë»ç³»°ú)
Åä·Ð 12-10 ´ë¾çAIȦ 12:10~12:20 Åä·Ð ()
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 12:20~12:40 Novel cardiovascular medication based on genetic test ¹Ú¿õ¾ç(¼º±Õ°üÀÇ´ë ºÐÀÚ¼¼Æ÷»ý¹°ÇÐ)
½Ä»ç 12-10 ´ë¾çAIȦ 12:40~13:30 ½Ä»ç ()
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 13:30~13:50 Diagnostic value of genetic tests in idiopathic primary arrhythmia syndrome À̱¤³ë(¾ÆÁÖÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 13:50~14:10 Development of devices for diagnosis of paroxysmal atrial fibrillation ±èÈÁß(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 14:10~14:30 Basic electrophysiologic study for supraventricular tachycardia ¾çÇʼº(Â÷ÀÇ°ú´ëÇÐ ½ÉÀå³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 14:30~14:50 ECG interpretation by artificial intelligence where we are? Á¶¿µÁø(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 12-10 ´ë¾çAIȦ 14:50~15:00 Åä·Ð ()
±³À°½Ã°£ 12-10 ÄÁÆÛ·±½º1-2 13:30~13:50 Cardiovascular physiology in the older adults ±è±¤ÀÏ(¼¿ïÀÇ´ë ³ëÀκ´³»°ú)
±³À°½Ã°£ 12-10 ÄÁÆÛ·±½º1-2 13:50~14:10 Antiplatelet strategy for stroke preventio ±è¿¹¸²(ÇѸ²ÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 12-10 ÄÁÆÛ·±½º1-2 14:10~14:30 Pharmacotherapy in Older Adults with cardiovascular disease ³ëÁÖÇö(ºÐ´ç¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ)
±³À°½Ã°£ 12-10 ÄÁÆÛ·±½º1-2 14:30~14:50 The role of cardiovascular pharmacists in geriatric teams: the time is now À̸̹®³»(¼¿ï¾Æ»êº´¿ø ¾àÁ¦ÆÀ)
Åä·Ð 12-10 ÄÁÆÛ·±½º1-2 14:50~15:00 Åä·Ð ()
ÈÞ½Ä 12-10 ´ë¾çAIȦ 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 15:20~15:40 Antiplatelet agents ÃßÀºÈ£(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 15:40~16:00 Anticoagulant agents ¼¿µÈÆ(°Ç¾çÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 16:00~16:20 Antihypertensive drugs ¾È¼Èñ(¿ï»êÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 12-10 ´ë¾çAIȦ 16:20~16:40 Prophylactic revascularization ÀÓ¿µÈ¿(ÇѾçÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 12-10 ´ë¾çAIȦ 16:40~16:50 Åä·Ð ()
±âŸ 12-10 ´ë¾çAIȦ 16:50~17:00 Æóȸ ()